[HTML][HTML] Management of secondary immunodeficiency in hematological malignancies in the era of modern oncology
N Shah, SS Mustafa, DC Vinh - Critical Reviews in Oncology/Hematology, 2023 - Elsevier
Secondary immunodeficiency (SID) in patients with B-cell hematological malignancies is a
common condition that presents with recurrent infection. SID is due to both the inherent …
common condition that presents with recurrent infection. SID is due to both the inherent …
[HTML][HTML] Vaccinations in hematological patients in the era of target therapies: Lesson learnt from SARS-CoV-2
B Fattizzo, N Rampi, W Barcellini - Blood Reviews, 2023 - Elsevier
Novel targeting agents for hematologic diseases often exert on-or off-target
immunomodulatory effects, possibly impacting on response to anti-SARS-CoV-2 …
immunomodulatory effects, possibly impacting on response to anti-SARS-CoV-2 …
Clinical Research in Chronic Lymphocytic Leukemia in Pakistan; A Systematic Review
M Ammad Ud Din, M Shahzad, A Ashraf, H Liaqat… - Medicina, 2023 - mdpi.com
Background: Significant advances have been made in the treatment of chronic lymphocytic
leukemia (CLL) since the turn of the new millennium. However, most clinical trials were done …
leukemia (CLL) since the turn of the new millennium. However, most clinical trials were done …
Vércsoport-szerológiai eltérések B-sejtvonalat érintő limfoproliferatív betegségekben
N Golács, K Szova, Á Szigeti Eszter… - Hematológia …, 2023 - akjournals.com
A vércsoport-szerológiai diagnosztika az antigén-antitest reakciókon alapszik. Az antitest
termeléséért felelős B-limfociták különböző szintű funkciózavarai a vércsoport-szerológiai …
termeléséért felelős B-limfociták különböző szintű funkciózavarai a vércsoport-szerológiai …
[引用][C] CLL Society's Official Statement on Boosters for CLL (Chronic Lymphocytic Leukemia) Patients
AZ Skarbnik, SS Mustafa - 2021